arrow
R

Roberto Bordonaro

Arnas Garibaldi Hospital
H指数:35
被引数:4,743

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Genomic profiling of high tumor mutational load in microsatellite-stable colorectal cancer uncovers MAPK signaling pathway alterations following anti-EGFR therapy

微卫星稳定型结直肠癌中高肿瘤突变负荷的基因组分析揭示了抗-EGFR治疗后MAPK信号通路的改变

2025-10-280
OAAI
Genomically matched therapy in advanced solid tumors: the randomized phase 2 ROME trial

基因组匹配疗法在晚期实体瘤中的应用:随机II期ROME试验

2025-09-290
OAAI
Non-Colorectal Liver Metastases Undergoing Liver Resection: The NONCOLMET Study Group

非结直肠癌肝转移接受肝脏切除术:NONCOLMET研究组

2025-09-010
PRE
Integrating tissue and liquid biopsy comprehensive genomic profiling to predict efficacy of anti-EGFR therapies in metastatic colorectal cancer: Findings from the CAPRI-2 GOIM study

整合组织与液体活检综合基因组分析以预测抗EGFR疗法在转移性结直肠癌中的疗效:CAPRI-2 GOIM研究的结果

2025-07-120
PRE
Trastuzumab plus lapatinib or chemotherapy in patients with HER2-overexpressed advanced breast cancer: a randomized, phase II trial (GIM12-TYPHER)

曲妥珠单抗联合拉帕替尼或化疗在HER2过表达的晚期乳腺癌患者中的应用:一项随机、II期试验(GIM12-TYPHER)

2025-07-010
OAAI
Adjuvant systemic therapy in early breast cancer and results of a prospective observational multicenter BRIDE study: patients outcome and adherence to guidelines in cancer clinical practice
2025-04-080
OAAI
Comprehensive genomic profiling by liquid biopsy portrays metastatic colorectal cancer mutational landscape to predict antitumor efficacy of FOLFIRI plus cetuximab in the CAPRI-2 GOIM trial

液体活检综合基因组分析描绘了转移性结直肠癌的突变景观,以预测CAPRI-2 GOIM试验中FOLFIRI联合西妥昔单抗的抗肿瘤疗效。

2025-04-010
PRE
Comprehensive genomic profiling by liquid biopsy captures tumor heterogeneity and identifies cancer vulnerabilities in patients with RAS/BRAFV600E wild-type metastatic colorectal cancer in the CAPRI 2-GOIM trial
2024-12-011
PRE
Evaluation of plasma assessed comprehensive genomic profiling before first-line treatment with FOLFIRI plus cetuximab in RAS/BRAFV600E wild type metastatic colorectal cancer patients in the CAPRI 2-GOIM trial
2024-06-011
PRE
Phase II randomized trial comparing metronomic anthracycline-containing chemotherapy versus standard schedule in untreated HER2 negative advanced breast cancer: activity and quality of life results of the GOIM 21003 trial

在未经治疗的HER2阴性晚期乳腺癌中,比较含节拍蒽环类药物的化疗与标准方案的II期随机试验: GOIM 21003试验的活性和生活质量结果

BREAST
IF7.9
2024-06-010
OAAI
Positive hyperselection of sensitizing genomic alterations (GAs) in RAS/BRAF wild-type (wt) metastatic colorectal cancer (mCRC) patients (pts) from the phase III study of first-line FOLFIRI/cetuximab versus FOLFIRI/cetuximab followed by cetuximab (Cet) alone (ERMES)
2024-06-010
PRE
Prognostic genomic signatures in RAS/BRAF mutant (mut) metastatic colorectal cancer (mCRC) patients (pts) from the phase II study of NIVolumab (niv) plus FOLFOXIRI/Bevacizumab (bev) in first-line therapy of Advanced COloRectal cancer (NIVACOR- GOIRC-03-2018)
2024-06-010
PRE
Characteristics and outcomes of immunotherapy-related liver injury in patients with hepatocellular carcinoma versus other advanced solid tumours

肝细胞癌患者与其他晚期实体瘤患者免疫治疗相关肝损伤的特征和结局

2024-03-0111
OA
Characteristics and outcomes of immunotherapy-related liver injury in patients with hepatocellular carcinoma compared to patients with advanced solid tumours
2024-02-010
PRE
Impact of influenza vaccination on survival of patients with advanced cancer receiving immune checkpoint inhibitors (INVIDIa-2): final results of the multicentre, prospective, observational study
2023-07-013
OAAI
Clinical efficacy of sequential treatments in KRASG12C-mutant metastatic colorectal cancer: findings from a real-life multicenter Italian study (CRC-KR GOIM)
2022-10-0111
OAAI
Phase III study with FOLFIRI/cetuximab versus FOLFIRI/cetuximab followed by cetuximab (Cet) alone in first-line therapy of RAS and BRAF wild-type (wt) metastatic colorectal cancer (mCRC) patients: The ERMES study
2022-09-017
OAAI